How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia

Bibliography

• Preskorn SH. The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol. J Psychiatr Pract 2007;13:253-7
   PubMedGoogle Scholar
• Citrome L. Lurasidone for schizophrenia, a brief review of a new second generation antipsychotic. Clin Schizophr Relat Psychoses 2011;4(4):251-7
   PubMedGoogle Scholar
• Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334:171-81
   PubMed Web of Science ®Google Scholar
• Latuda [package insert] Marlborough, MA: Sunovion Pharmaceuticals. Issued 2013. Available from: www.latuda.com/LatudaPrescribingInformation.pdf [Last Accessed 14 May 2015]
   Google Scholar
• Ishiyama T, Tokuda K, Ishibashi T, et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007;572:160-70
   PubMed Web of Science ®Google Scholar
• Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65(2):189-210
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):950-62
   Google Scholar
• Prices were checked with local Walmart pharmacy
   Google Scholar
• Chiu Y, Ereshefsky L, Preskorn S, et al. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact 2014;29(3):191-202
   PubMedGoogle Scholar
• Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol 2011;7(7):829-46
   PubMed Web of Science ®Google Scholar
• Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr Dis Treat 2012;8:155-68
   PubMed Web of Science ®Google Scholar
• Preskorn S. Clinically Important differences in the pharmacokinetics of the ten newer “atypical” antipsychotics. J Psychiatr Pract 2012;18(6):430-7
   PubMed Web of Science ®Google Scholar
• Guidance for Industry, E 10 choice of control group and related issues in clinical trials. US Department of health and human services, FDA, 2001
   Google Scholar
• Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl) 2013;225(3):519-30
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(6):829-36
   PubMed Web of Science ®Google Scholar
• Meltzer H, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011;168:957-67
   PubMed Web of Science ®Google Scholar
• Nasrallah H, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res 2013;47(5):670-7
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 2013;145(1-3):101-9
   PubMed Web of Science ®Google Scholar
• Sunovion D1050049, A Randomized, Double – Blind, Placebo-and haloperidol -Controlled study
   Google Scholar
• Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12 months, double double-blind, noninferiority study. Schizophr Res 2013;147(1):95-102
   PubMed Web of Science ®Google Scholar
• Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 2012;27(3):165-76
   PubMed Web of Science ®Google Scholar
• Abilify (aripiprazole) prescribing information. Otsuka America Pharmaceutical, Inc. Revised 2012. Available from: www.otsuka-us.com/Documents/Abilify.PI.pdf [Last Accessed 1 Jun 2015]
   Google Scholar
• Saphris (asenapine) prescribing information. Actavis, Inc. Revised 2015. Available from: http://pi.actavis.com/data_stream.asp?product_group=1908&p=pi&language=E [Last Accessed 1 June 2015]
   Google Scholar
• Clozaril (clozapine) prescribing information. Novartis Pharmaceuticals. Revised 2014. Available from: www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf [Last Accessed 1 Jun 2015]
   Google Scholar
• Fanapt (iloperidone) prescribing information. Revised 2014, Vanda Pharmaceuticals Inc. Available from: www.fanapt.com/product/pi/pdf/fanapt.pdf [Last Accessed 1 June 2015]
   Google Scholar
• Zyprexa (olanzapine) prescribing information. Revised 2014.Lilly USA, LLC Available from: http://pi.lilly.com/us/zyprexa-pi.pdf [Last Accessed 1 June 2015]
   Google Scholar
• Invega (paliperidone) prescribing information. Janssen Pharmaceuticals. 2011. Available from: www.invegasustenna.com/important-product-information [Last Accessed 4 May 2012]
   Google Scholar
• Seroquel (quetiapine) prescribing information. AstraZeneca Pharmaceuticals LP. Revised 2013. Available from: www1.astrazeneca-us.com/pi/Seroquel.pdf [Last Accessed 1 Jun 2015]
   Google Scholar
• Risperdol (risperidone) prescribing information. Janssen Pharmaceuticals. 2011. Available from: www.risperdal.com/prescribing.html [Last Accessed 4 May 2012]
   Google Scholar
• Geodon (ziprasidone) prescribing information. Pfizer Inc. Revised 2014. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=584 [Last Accessed 1 June 2015]
   Google Scholar
• Haldol (haloperidol) prescribing information. Janssen Pharmaceuticals. Revised 2013. Available from: www.janssenmd.com/pdf/haldol-d/PI-Haldol-Decanoate.pdf [Last Accessed 28 May 2015]
   Google Scholar
• Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsycholpharmacology 1998;18(2):63-101
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on new generation compounds. Life Sci 2000;68(1):29-39
   PubMed Web of Science ®Google Scholar
• Bymaster F, Dreshfield-Ahmad L, Threlkeld P, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25(6):871-80
   PubMed Web of Science ®Google Scholar
• Leonard B, Richelson E. Synaptic effects of antidepressants: relation to their therapeutic and adverse effects. In: Buckley P, Waddington J, editors, Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Oxford University Press/A Hodder Arnold Publication; New York: NY: 2000. p. 67-84
   Google Scholar